Thursday, November 17, 2005
Rosacea and dobesilate
Looks interesting, will try and write more later when I have more time:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16287608&dopt=Abstract
Eur J Med Res. 2005 Oct 18;10(10):454-456.
Therapeutic Response of Rosacea to Dobesilate.
Cuevas P, Arrazola JA.
Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid - Spain.
Despite an incomplete understanding of the pathogenesis of rosacea, therapeutic modalities continue to expand. The principal subtype of rosacea includes erythematotelangiestatic rosacea, which is characterized by uncontrolled angiogenesis. Angiogenic growth factors such as fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF) are currently targets of intense effort to inhibit deregulated blood vessel formation in diseases such as cancer. Here we report a 33-years-old woman with erythematotelangestatic rosacea who responds to a daily treatment of topically applied dobesilate, an inhibitor of FGF, with an improvement in erythema and telangectasia after two weeks. Thus, dobesilate might be useful in the treatment of rosacea and other diseases that depend on pathologic angiogenesis.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16287608&dopt=Abstract
Eur J Med Res. 2005 Oct 18;10(10):454-456.
Therapeutic Response of Rosacea to Dobesilate.
Cuevas P, Arrazola JA.
Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid - Spain.
Despite an incomplete understanding of the pathogenesis of rosacea, therapeutic modalities continue to expand. The principal subtype of rosacea includes erythematotelangiestatic rosacea, which is characterized by uncontrolled angiogenesis. Angiogenic growth factors such as fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF) are currently targets of intense effort to inhibit deregulated blood vessel formation in diseases such as cancer. Here we report a 33-years-old woman with erythematotelangestatic rosacea who responds to a daily treatment of topically applied dobesilate, an inhibitor of FGF, with an improvement in erythema and telangectasia after two weeks. Thus, dobesilate might be useful in the treatment of rosacea and other diseases that depend on pathologic angiogenesis.
